Could a common HIV drug save new lungs?
NCT ID NCT06853223
First seen Jan 31, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study tests whether Maraviroc, a drug already approved for HIV, can prevent severe lung injury (primary graft dysfunction) after a lung transplant. About 120 adults at high risk for this complication will receive either Maraviroc or a placebo every 12 hours for 3 days after surgery. Researchers will monitor participants during their hospital stay and for 12 months after to see if the drug reduces lung damage and improves recovery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER CELL MEDIATED IMMUNITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.